Home>Topics>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. BTD tag for Eylea for diabetic retinopathy in DME

      Headlines

      Tue, 16 Sep 2014

      The FDA designates Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea ( aflibercept ) a Breakthough Therapy (BTD) for the treatment of diabetic retinopathy in patients with diabetic macular

    2. Celgene Looks Unstoppable

      Headlines

      Mon, 15 Sep 2014

      company is a cohort in a quartet of large, powerful bio-pharmas. The others are Gilead (NASDAQ: GILD ), Regeneron (NASDAQ: REGN ) and Biogen Idec (NASDAQ: BIIB ). Management is deep and well-respected. Chairman / CEO Robert Hugin has executive experience

    3. Cramer's Mad Money - Where Did The Investors Go? (9/8/14)

      Headlines

      Tue, 9 Sep 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday September 8. Where Did The Investors Go? General Mills (NYSE: GIS ), Annie's (NYSE: BNNY ), Hain Celestial (NASDAQ: HAIN ), Mobileye (NYSE: MBLY ), GoPro (NASDAQ: GPRO ), Bob Evans

    4. Sanofi: Riding The Growth Trend

      Headlines

      Mon, 8 Sep 2014

      valuation. Positive Data from Sanofi and Regeneron Pharmaceutical's Cholesterol Drug Sanofi and Regeneron Pharmaceuticals (NASDAQ: REGN ) recently announced positive results from a Phase 3 ODYSSEY trial of Alirocumab in people with hypercholesterolemia

    5. There Is Further Upside Potential In Regeneron Pharmaceuticals

      Headlines

      Mon, 8 Sep 2014

      By Kanak Kanti De : In a year that has seen biotechnology stocks struggle in general, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) is an exception. Shares of the biotechnology company are up more than 25% so far this year

    6. Challenging Consensus On PCSK9 Inhibitors: Focus On Regeneron And Amgen

      Headlines

      Mon, 8 Sep 2014

      companies Amgen (NASDAQ: AMGN ) and Regeneron (NASDAQ: REGN ). (The protein's full name is proprotein convertase ..... The companies supporting this site include AMGN and REGN , REGN 's joint venture partner Sanofi (NYSE: SNY ), Pfizer

    7. Cramer's Mad Money - 3 Wide Receiver Stocks (9/4/14)

      Headlines

      Fri, 5 Sep 2014

      NASDAQ: TSLA ), Netflix (NASDAQ: NFLX ), Regeneron (NASDAQ: REGN ). Other stocks mentioned: Teva (NYSE: TEVA ), Perrigo ..... winning content. The stock has risen 30% for 2014. Regeneron ( REGN ) was one of Cramer's first Mad Money picks and has rallied

    8. Bayer subsidiary submits marketing app for Eylea label expansion in Japan

      Headlines

      Thu, 4 Sep 2014

      applications for Eylea for the treatment of choroidal neovascularization secondary to pathologic myopia and for the treatment of diabetic macular edema are currently under regulatory review. Related ticker: ( REGN +0.7% ) Post your comment!

    9. Cramer's Mad Money - Fascinating Schisms (9/2/14)

      Headlines

      Wed, 3 Sep 2014

      Caremark (NYSE: CVS ), McKesson (NYSE: MCK ), Perrigo (NYSE: PRGO ), Mallinckrodt (NYSE: MNK ), Regeneron (NASDAQ: REGN ), Gilead (NASDAQ: GILD ) and Celgene (NASDAQ: CELG ), Union Pacific (NYSE: UNP ), Norfolk Southern (NYSE: NSC

    10. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      have dramatically outperformed the broader market over the past five years. Some firms held in this ETF, such as Regeneron REGN , Biogen Idec BIIB, Celgene CELG, Gilead GILD, and Amgen AMGN, have led the rally, benefiting from key drug approvals

    « Prev12345Next »
    Content Partners